Sector News

Israel's BrainStorm names Biogen senior executive Kern as COO

March 7, 2017
Life sciences

Israel’s BrainStorm Cell Therapeutics, which is developing an adult stem cell treatment for patients with amyotrophic lateral sclerosis (ALS), on Monday named Ralph Kern as chief operating officer.

Kern, who has also been named chief medical officer, joins BrainStorm from Biogen, where he was senior vice president and head of worldwide medical. At Biogen he helped define the company’s therapeutic area and scientific strategies for Alzheimer’s disease, multiple sclerosis, spinal muscular atrophy, Parkinson’s, neurodegeneration and hemophilia.

He was previously head of the neuroscience medical unit at Novartis and global medical director of personalized genetic health at Genzyme Corp.

BrainStorm is preparing to conduct a Phase 3 clinical trial for its NurOwn treatment at multiple sites in the United States and Israel. The company has said the advanced trial is expected to begin enrolling patients in the second quarter.

“I am confident that BrainStorm will become the world leader in adult stem cell therapies for neurodegenerative disorders,” Kern said.

By Tova Cohen

Source: Reuters

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.